Cyclosporin A-Immunobiological Aspects
1982; Lippincott Williams & Wilkins; Volume: 2; Issue: 5 Linguagem: Espanhol
10.1002/hep.1840020519
ISSN1527-3350
Autores Tópico(s)Blood groups and transfusion
ResumoHepatologyVolume 2, Issue 5 p. 645S-647S ArticleFree Access Cyclosporin A–Immunobiological Aspects Peter J. Tutschka M.D., Corresponding Author Peter J. Tutschka M.D. The Johns Hopkins University School of Medicine Oncology Center 3–127 Baltimore, Maryland 21205Peter J. Tutschka, M.D., The Johns Hopkins Oncology Center 3–127, 600 North Wolfe Street, Baltimore, Maryland 21205.===Search for more papers by this author Peter J. Tutschka M.D., Corresponding Author Peter J. Tutschka M.D. The Johns Hopkins University School of Medicine Oncology Center 3–127 Baltimore, Maryland 21205Peter J. Tutschka, M.D., The Johns Hopkins Oncology Center 3–127, 600 North Wolfe Street, Baltimore, Maryland 21205.===Search for more papers by this author First published: September/October 1982 https://doi.org/10.1002/hep.1840020519Citations: 4AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Ehrlich P. Gesammelte Arbeiten zur Immunitatsforschung Hirschwald Berlin: 1904. 2 Brent L, Brooks CG, Medawar PB, et al. Transplantation tolerance. Br Med Bull 1976; 32: 101– 106. 3 McBurnett FM. The clonal selection theory of acquired immunity. Cambridge: Cambridge University Press, 1959. 4 Billingham RE, Brent L, Medawar PB. Trans R Soc Lond B 1965; 234: 357. 5 Allison AC, Dennon AM. Self-tolerance and autoimmunity. Br Med Bull 1976; 32: 124– 129. 6 Owen RD. Immunogenetie consequences of vascular anastomoses between bovine twins. Science 1945; 102: 400. 7 Cerilli J. Presidential address: role of kidney transplantation and its implementation. Transplantation 1981; 32: 459– 462. 8 Najarian JS, Archer NL. Causes and management of rejection. Transplant Proc 1979; 11: 11– 16. 9 Naik RB, Abdeen H, English J, et al. Prednisone withdrawal after two years in renal transplant patients receiving only this form of immunosuppression. Transplant Proc 1979; 11: 39– 44. 10 Tutschka PJ. Cyclosporin A–A new outlook for immunosuppression in clinical transplantation. BLUT 1979; 39: 81– 87. 11 Slavin S, Strober S. J Immunol 1979; 123: 942. 12 Borel JF, Feurer C, Gubler HU, et al. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents and Actions 1976; 6: 468– 475. 13 Borel JF, Feurer C, Magnee C, et al. Effects of the new antilymphocyte peptide cyclosporin A in animals. Immunology 1977; 32: 1017. 14 Burkhardt JJ, Guggenheim B. Cyclosporin A: in vivo and in vitro suppression of rat T-lymphocyte function. Immunology 1979; 36: 753– 757. 15 Kostakis AJ, White DJG, Calne RY. Prolongation of rat heart allograft survival by cyclosporin A. IRCS J Med Sci 1977; 5: 280. 16 Calne RJ, White DJG, Rolles K, et al. Prolonged survival of pig arthotopic heart grafts treated with cyclosporin A. Lancet 1978; 1: 1183– 1185. 17 Calne RY, White DJG. Cyclosporin A–A powerful immunosuppressant in dogs with renal allografts. IRCS J Med Sci 1977; 5: 595. 18 Green CL, Allison AC. Extensive prolongation of rabbit kidney allograft after short-term Cyclosporin A treatment. Lancet 1978; 1: 1182– 1183. 19 Tutschka PJ, Beschorner WE, Allison AC, et al. Use of cyclosporin A in allogeneic bone marrow transplantation in the rat. Nature 1979; 280: 148– 151. 20 Tutschka PJ, Beschorner WE, Hess AD, et al. Use of cyclosporin A (CsA) in a rat model of allogeneic marrow transplantation. BLUT 1980; 25: 241– 253. 21 Deeg HJ, Storb R, Weiden PL, et al. Cyclosporin A: effect on marrow engraftment and graft-versus-host disease in dogs. Transplant Proc 1981; 13: 402. 22 Tutschka PJ, Hess AD, Beschorner WE, et al. Cyclosporin A in bone marrow transplantation–Baltimore experience in preclinical studies. In: SJ Baum, GD Ledney, A Khan, eds. Experimental hematology today. New York: S. Karger, 1981: 99– 106. 23 Leorin P, Garcia RC, Allison AC. Effects of cyclosporin A on human lymphocytes in culture. J Clin Lab Immunol 1978; 1: 67. 24 Leapman SB, Filo RS, Smith EJ, et al. Differential effects of cyclosporin A on lymphocyte subpopulations. Transplant Proc 1981; 13: 405. 25 Horsburgh T, Wood P, Brent L. Suppression of in vitro lymphocyte reactivity by cyclosporin A: existence of a population of drug resistant cytotoxic lymphocytes. Nature 1980; 286: 609. 26 Wang BS, Heacock EH, Collins KH, et al. Suppressive effects of cyclosporin A on the induction of alloreactivity in vitro and in vivo. J Immunol 1981; 127: 89– 93. 27 White DJG, Plumb AM, Pawelec G, et al. Cyclosporin A: an immunosuppressive agent preferentially active against proliferating T-cells. Transplantation 1979; 27: 55. 28 Hess AD, Tutschka PJ, Santos GW. Effect of cyclosporin A on human mixed lymphocyte responses. Induction of operational tolerance to alloantigens in vitro. Transplant Proc 1981; 13: 374– 378. 29 Hess AD, Tutschka PJ, Santos GW. Effect of cyclosporin A on human mixed lymphocyte responses. II. Induction of specific alloantigen unresponsiveness mediated by a nylon wool adherent suppressor cell. J Immunol 1981; 126: 961– 968. 30 Hess AD, Tutschka PJ, Santos GW. Effect of cyclosporin A on human mixed lymphocyte responses in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response to primed lymphocytes to TCGF. J Immunol 1982; 128: 355– 359. 31 Larsson ES. Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process. J Immunol 1980; 124: 2828– 2833. 32 Bunjes D, Hardt C, Rolllinghoft M, et al. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol 1981; 11: 657. 33 Hess AD, Tutschka PJ, Santos GW. Effect of cyclosporin A on human mixed lymphocyte responses in vitro. IV. Production of T cell stimulatory growth factors and development of responsiveness to these growth factors in CsA treated primary MLR cultures. J Immunol 1982; 128: 360– 367. 34 Palacios R, Moller G. Cyclosporin A blocks receptors for HLA-DR antigens on T cells. Nature 1981; 290: 792. 35 Reitz BA, Bieber CP, Raney AA, et al. Orthotopic heart and combined heart and lung transplantation with cyclosporin A immune suppression. Transplant Proc 1981; 13: 390– 392. 36 Calne RY, Rolles K, White DJ, et al. Cyclosporin A in clinical organ grafting. First Northern Ireland Kidney Research Fund Lecture. Olster Med J 1981; 50: 62– 70. 37 Starzl TE, Klintmalm GB, Porter KA, et al. Liver transplantation with use of cyclosporin A and prednisone. N Engl J Med 1981; 305: 266– 269. 38 Morris PJ. Cyclosporin A. Transplantation 1981; 32: 349– 354. 39 Klintmalm GB, Iwatsuki S, Starzl TE. Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet 1981; 1: 470– 471. 40 Gluckman E, Divergie A, Lokiec F, et al. Nephrotoxicity of cyclosporin A in bone marrow transplantation. Lancet 1981; 2: 144– 145. 41 Starzl TE, Klintmalm GB, Weil R, et al. Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet 1981; 153: 486– 494. 42 Powles RL, Clink HM, Spelice D, et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone marrow transplantation. Lancet 1980; 1: 327. 43 Hutchinson IF, Shadur CA, Alberto-Duarte JS, et al. Cyclosporin A spares selectively lymphocytes with donor-specific suppressor characteristics. Transplantation 1981; 32: 210– 216. 44 Nagao AT, White DJG, Calne RY. Kinetics of unresponsiveness induced by a short course of cyclosporin A. Transplantation 1982; 33: 31– 35. 45 Deeg JH, Storb R, Gerhard-Miller L, et al. Cyclosporin A, a powerful immunosuppressant in vivo and in vitro in the dog, fails to induce tolerance. Transplantation 1980; 29: 230. 46 Rynasiewicz JJ, Sutherland DE, Kawahara K, et al. Total lymphoid irradiation in rat heart allografts: dose, fractionation, and combination with cyclosporin A. Transplant Proc 1981; 13: 452– 454. 47 Penn I. Tumor incidence in human allograft recipients. Transplant Proc 1979; 11: 1047– 1051. 48 Bird AG, McLachlan SM, Britton S. Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein-Barr virus-induced B-cell lines. Nature 1981; 289: 300– 301. 49 Calne RY, Rolles K, White DJG. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs, 32 kidneys, 2 pancreases and 2 livers. Lancet 1979; 2: 1033– 1036. 50 Pennock JL, Reitz BA, Bieber CP, et al. Cardiac allograft survival in cynomolgus monkeys treated with cyclosporin A in combination with conventional immune suppression. Transplant Proc 1981; 12: 390– 392. 51 Starzl, TE, Iwatsuki S, Van Thiel DH, et al. Evolution of liver transplantation. Hepatology 1981; 2: 614– 636. 52 Tutschka PJ, Hess AD, Beschorner WE, et al. Cyclosporin A in allogeneic bone marrow transplantation. Preclinical and clinical studies. In: DJG White, RY Calne, eds. International symposium on cyclosporin A. Amsterdam: Elsevier/North Holland Biomedical Press V.B., 1982 (in press). Citing Literature Volume2, Issue5September/October 1982Pages 645S-647S ReferencesRelatedInformation
Referência(s)